



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Asst. Commissioner for Patents, Washington, D.C. 20231
on 9/12/01
By: Alene C. Granlee

PATENT
Attorney Docket No.: 16663-000120US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

JOHN R. CASHMAN et al.

Application No.: 09/583,310

Filed: May 30, 2000

For: DNA SEQUENCE ENCODING
FLAVIN-CONTAINING
MONOOXYGENASE

Examiner: P. Tung

Art Unit: 1652

PRELIMINARY AMENDMENT

TECH CENTER 1652/2900

SEP 20 2001

RECEIVED

5/a
A99
9/21/01

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Notice to Comply with Sequence Disclosures, mailed May 8, 2001, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Kindly amend the specification as follows:

Please replace the paragraph beginning at page 10, line 19, with the following paragraph:

a¹
The complete nucleotide sequence of the HLFMO 3 cDNA was determined. It contained a 5'-untranslated region of 136 bp, followed by an open reading frame (ORF) of 1599 bp, encoding a protein of Mr 159,179, a termination codon and a 3'-untranslated region of 384 bp. The sequence ACCATGG (SEQ ID No. 9; (bp 134-140)) contained the initiating codon ATG and corresponded to the sequence found to be optimal for initiation of transcription by eukaryotic ribosomes (Kozak, Cell 44, 283-292 (1986)).